Edwards Lifesciences welcomes CMS update to Medicare TAVR coverage policy
Reuters2026/09/10 21:49- Edwards Lifesciences welcomed CMS’ updated national coverage determination for TAVR, citing improved access and greater Heart Team flexibility.
- Policy update seen as supporting faster evaluation and treatment for aortic stenosis, which Edwards linked to better outcomes and lower costs.
- Implementation expected to take time; Edwards reiterated confidence in its previously issued 2026 financial guidance.
- 2027 and longer-term guidance slated for December at the company’s investor conference.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Intel-supported chip manufacturer Altera plans to go public this year, with a financing scale expected to exceed 2 billions USD.
According to media reports citing sources familiar with the matter, chipmaker Altera, backed by private equity giant Silver Lake and Intel, is preparing to confidentially file for an initial public offering (IPO), which could take place as soon as this year. The IPO is expected to raise more than 2 billions USD.

NPKI Chief Accounting Officer Warren Matthew James disposes of USD 40,112 in common shares
GSI Technology VP, Taiwan Operations Bor-Tay Wu files initial beneficial ownership statement
nLIGHT CEO Scott H. Keeney disposes of common shares worth $8.82 million